Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Nov;7(6):771-775.
doi: 10.21037/acs.2018.08.04.

MitraClip patient selection: inclusion and exclusion criteria for optimal outcomes

Mario Gössl  1 , Paul Sorajja  1
Affiliations
Editorial

MitraClip patient selection: inclusion and exclusion criteria for optimal outcomes

Mario Gössl et al. Ann Cardiothorac Surg. 2018 Nov.

Abstract

Edge-to-edge repair with the percutaneous MitraClip technology has changed the landscape for patients with symptomatic, severe degenerative mitral valve regurgitation who are at prohibitive surgical risk. While the results of randomized controlled trials of MitraClip therapy in patients with functional mitral valve regurgitation are still pending, single center experiences as well as registry data generally support the real-world application of the MitraClip therapy. In the majority of individuals treated with MitraClip, complete or near-complete relief of mitral regurgitation occurs, with results approaching the effectiveness of open surgery. This perspective summarizes the data, with a focus on current selection criteria of percutaneous MitraClip edge-to-edge repair that can optimize clinical outcomes.

Keywords: MitraClip; degenerative mitral valve regurgitation (DMR); functional mitral valve regurgitation (FMR); inclusion exclusion criteria.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sorajja P, Mack M, Vemulapalli S, et al. Initial Experience With Commercial Transcatheter Mitral Valve Repair in the United States. J Am Coll Cardiol 2016;67:1129-40. 10.1016/j.jacc.2015.12.054 - DOI - PubMed
    1. Whitlow PL, Feldman T, Pedersen WR, et al. Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study. J Am Coll Cardiol 2012;59:130-9. 10.1016/j.jacc.2011.08.067 - DOI - PubMed
    1. Obadia JF, Armoiry X, Iung B, et al. The MITRA-FR study: design and rationale of a randomised study of percutaneous mitral valve repair compared with optimal medical management alone for severe secondary mitral regurgitation. EuroIntervention 2015;10:1354-60. 10.4244/EIJV10I11A232 - DOI - PubMed
    1. Mauri L, Garg P, Massaro JM, et al. The EVEREST II Trial: design and rationale for a randomized study of the evalve mitraclip system compared with mitral valve surgery for mitral regurgitation. Am Heart J 2010;160:23-9. 10.1016/j.ahj.2010.04.009 - DOI - PubMed
    1. Lesevic H, Karl M, Braun D, et al. Long-Term Outcomes After MitraClip Implantation According to the Presence or Absence of EVEREST Inclusion Criteria. Am J Cardiol 2017;119:1255-61. 10.1016/j.amjcard.2016.12.027 - DOI - PubMed

Publication types